New stock news | Haina Pharmaceuticals' Hong Kong stock IPO prospectus invalidated.

Nanjing Haina Pharmaceutical Technology Co., Ltd. (referred to as Haina Medicine) submitted its Hong Kong IPO prospectus on November 7, 2025, which expired on May 7, 2026, six months after submission, with CICC as its exclusive sponsor at the time of submission. According to the previous prospectus, Haina Medicine is an integrated pharmaceutical research and manufacturing company that provides CXO services; at the same time, the company has a proprietary product pipeline that is mainly commercialized through pharmaceutical technology transfer. According to a Frost & Sullivan report, during the historical performance period and up to the last practicable date (November 2, 2025), Haina Medicine ranked second among CXO service providers in China engaged in drug technology transfer, in terms of the total number of approved clinical trials and market approvals. According to the same source, Haina Medicine also ranked second in terms of the total number of clinical trial and market approval applications submitted during the same period.